2025: The Inflammatory Bowel Disease (IBD) Year in Review
Abstract
Effective and well-tolerated dietary therapies for Crohn’s disease have long been sought by both patients and providers. In pediatric inflammatory bowel disease (IBD), exclusive enteral nutrition (EEN) has gained traction and is recommended by treatment guidelines. However, it has not been broadly implemented in adults due to poor tolerability, social constraints, and challenges with long-term adherence. Consequently, there is a growing interest in dietary interventions that offer efficacy while imposing a lower burden on patients.
TASTI-MM is the first randomized controlled trial to provide evidence supporting an exclusive whole-food dietary strategy to treat active Crohn’s disease. Previous evidence for whole‑food approaches was limited to observational cohorts. This trial sought to determine whether a whole food diet could enhance compliance in comparison with EEN, improve disease activity, and modify the microbiome with the goal of sustained disease control.
References
Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2021;15(2):jjaa161. doi:10.1093/ecco-jcc/jjaa161
Swaminath A, Feathers A, Ananthakrishnan A, Falzon L, Ferry SL. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2017;46(7):645-656. doi:10.1111/apt.14253
Correia I, Oliveira PA, Antunes ML, Raimundo MdG, Moreira AC. Is there evidence of Crohn’s disease exclusion diet in remission of active disease in children and adults: a systematic review. Nutrients. 2024;16(7):987. doi:10.3390/nu16070987
Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440-450.e8. doi:10.1053/j.gastro.2019.04.021
Aharoni-Frutkoff Y, Plotkin L, Pollak D, Livovsky J, Focht G, Lev-Tzion R, et al. Whole food diet induces remission in children and young adults with mild to moderate Crohn’s disease and is more tolerable than exclusive enteral nutrition: a randomized trial. Gastroenterology. 2025;169(7):1462-1474.e2. doi:10.1053/j.gastro.2025.06.011
Hashash JG, Elkins J, Lewis JD, Binion DG. AGA clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review. Gastroenterology. 2024;16(3)6:521-532. doi:10.1053/j.gastro.2023
Boneh RS, Assa A, Lev-Tzion R, Matar M, Shouval D, Shubeli C, et al. Adherence to the Mediterranean diet is associated with decreased fecal calprotectin levels in children with Crohn’s disease in clinical remission under biological therapy. Dig Dis. 2024;42(2):199-210. doi:10.1159/000535540
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease. Gastroenterology. 2021;161(3):837-852.e9. doi:10.1053/j.gastro.2021.05.047
Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology. 2019;156(5):1354-1367.e6. doi:10.1053/j.gastro.2018.12.002
Häcker D, Siebert K, Smith BJ, Köhler N, Riva A, Mahapatra A, et al. Exclusive enteral nutrition initiates individual protective microbiome changes to induce remission in pediatric Crohn’s disease. Cell Host Microbe. 2024;32(11):2019-2034.e8. doi:10.1016/j.chom.2024.10.001
Lightner AL, Ashburn JH, Brar MS, Carvello M, Chandrasinghe P, van Overstraeten AB, et al. Fistulizing Crohn’s disease. Curr Probl Surg. 2020;57(11):100808. doi:10.1016/j.cpsurg.2020.100808
Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of perianal Crohn’s disease: a systematic review and meta-analysis of population-based cohorts. Inflamm Bowel Dis. 2022;28(10):1477-1484. doi:10.1093/ibd/izab287
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122 (4):875-880. doi:10.1053/gast.2002.32362
Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in Crohn’s disease. N Engl J Med. 1999;340(6):1398-1405. doi:10.1056/NEJM199905063401804
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for Crohn’s disease. N Engl J Med. 2004;350(9):876-885. doi:10.1056/NEJMoa030815
Gold SL, Cohen-Mekelburg S, Schneider Y, Steinlauf A. Perianal fistulas in patients with Crohn’s disease, part 1: current medical management. Gastroenterol Hepatol (N Y). 2018;14(8):470-481.
Geldof J, Iqbal N, LeBlanc J-F, Anandabaskaran S, Sawyer R, Buskens C, et al. Classifying perianal fistulising Crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol. 2022;7(6):576-584. doi:10.1016/S2468-1253(22)00007-3
Loftus EV Jr, Panès J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966-1980. doi:10.1056/NEJMoa2212728
Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, et al. Efficacy and safety of upadacitinib for perianal fistulizing Crohn’s disease: a post hoc analysis of 3 phase 3 trials. Clin Gastroenterol Hepatol. 2025;23(6):1019-1029. doi:10.1016/j.cgh.2024.08.032
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomized, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024;9(2):133-146. doi:10.1016/S2468-1253(23)00318-7
Sandborn WJ, D’Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-1664.e8. doi:10.1053/j.gastro.2022.01.047
Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised double-blind controlled phase 2 proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307-320. doi:10.1016/S2468-1253(22)00427-7
Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Systematic review with meta-analysis: contemporary rates of surgery in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(10):2031-2045.e11. doi:10.1016/j.cgh.2020.10.039
Oldenburg L, Haanappel AEG, Ali M, Bosman C, Buskens CJ, Ponsioen CY, et al. Ileocaecal resection versus infliximab for ileal Crohn’s disease: retrospective 10-year follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2026;11(4):314-322. doi:10.1016/S2468-1253(25)00374-7
Agrawal M, Ebert AC, Poulsen G, Ungaro RC, Faye AS, Jess T, et al. Early ileocecal resection for Crohn’s disease Is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: a population-based cohort study. Gastroenterology. 2023;165(4):976-985.e3. doi:10.1053/j.gastro.2023.05.051
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-963. doi:10.1016/0016-5085(90)90613-6
D’Haens G, Taxonera C, Lopez-Sanroman A. Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025;10(1):26-33. doi:10.1016/S2468-1253(24)00317-0
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150(7):1568-1578. doi:10.1053/j.gastro.2016.02.072
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406-1417. doi:10.1016/S0140-6736(14)61908-5
Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2025;120(6):1225-1264. doi:10.14309/ajg.0000000000003465
Barnes EL, Herfarth HH, Kappelman MD, Zhang X, Lightner A, Long MD, et al. Incidence, risk factors, and outcomes of pouchitis and other pouch-related disorders after ileal pouch–anal anastomosis. Clin Gastroenterol Hepatol. 2021;19(8):1583-1591.e4. doi:10.1016/j.cgh.2020.06.035.
Samaan MA. Editorial: biologic therapy for chronic pouchitis. Are we beginning to meet the unmet need? Aliment Pharmacol Ther. 2018;47(6):857-858. doi:10.1111/apt.14542
Travis S, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Jairath V, et al. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med. 2023;388(13):1191-1200. doi:10.1056/NEJMoa2208450
Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505-512. doi:10.1016/s0016-5107(04)01878-4
Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;619(12):409-415. doi:10.1016/s0025-6196(12)61634-6
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
